Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Chemomab Therapeutics Ltd DRC (CMMB)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: CMMB (3-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
AI Based Fundamental Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Analysis of Past Performance
Type Stock | Historic Profit -13.97% | Avg. Invested days 22 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 19.61M USD | Price to earnings Ratio - | 1Y Target Price 9 |
Price to earnings Ratio - | 1Y Target Price 9 | ||
Volume (30-day avg) 657221 | Beta 0.49 | 52 Weeks Range 0.58 - 2.55 | Updated Date 04/2/2025 |
52 Weeks Range 0.58 - 2.55 | Updated Date 04/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.86 |
Earnings Date
Report Date 2025-03-05 | When Before Market | Estimate -0.01 | Actual -0.008 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -47.1% | Return on Equity (TTM) -91.34% |
Valuation
Trailing PE - | Forward PE 13 | Enterprise Value 5668875 | Price to Sales(TTM) - |
Enterprise Value 5668875 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 0.33 | Shares Outstanding 18856600 | Shares Floating 236378933 |
Shares Outstanding 18856600 | Shares Floating 236378933 | ||
Percent Insiders 15.9 | Percent Institutions 25.92 |
Analyst Ratings
Rating 4.33 | Target Price 8 | Buy 2 | Strong Buy 1 |
Buy 2 | Strong Buy 1 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Chemomab Therapeutics Ltd DRC
Company Overview
History and Background
Chemomab Therapeutics Ltd DRC, founded to discover and develop innovative therapeutics for fibrotic and inflammatory diseases. It focuses on leveraging its platform to develop novel antibodies targeting CCL24.
Core Business Areas
- Therapeutic Development: Focused on developing CM-101, a monoclonal antibody targeting CCL24, for the treatment of rare and severe fibrotic diseases like SSc (Systemic Sclerosis).
- Research and Development: Ongoing research to explore additional applications for CCL24 inhibition in various fibrotic and inflammatory conditions.
Leadership and Structure
Chemomab is led by a management team with expertise in drug development and biotechnology. Details about specific leadership roles and the complete organizational structure would require access to proprietary information, which is generally available on the company website or in the investor relations section.
Top Products and Market Share
Key Offerings
- CM-101: CM-101 is Chemomab's lead product candidate, a monoclonal antibody targeting CCL24. It is currently in clinical development for Systemic Sclerosis (SSc). Market share is N/A as the drug is still in clinical trials. Competitors include companies developing therapies for SSc, such as Actelion (acquired by Johnson & Johnson) and Boehringer Ingelheim.
Market Dynamics
Industry Overview
The biopharmaceutical industry focuses on developing therapies for various diseases. The market for fibrotic diseases is substantial and growing, reflecting unmet medical needs.
Positioning
Chemomab is positioned as a company focused on developing novel therapies targeting CCL24 for fibrotic and inflammatory diseases. Its competitive advantage lies in its specific antibody and its targeted approach.
Total Addressable Market (TAM)
The TAM for Systemic Sclerosis and other fibrotic diseases is significant and estimated to be in the billions of dollars. Chemomab's positioning relies on successfully developing and commercializing CM-101 to capture a portion of this market.
Upturn SWOT Analysis
Strengths
- Novel CCL24-targeting antibody (CM-101)
- Focus on unmet medical needs in fibrotic diseases
- Experienced management team
Weaknesses
- Dependence on single product candidate (CM-101)
- Limited financial resources
- High risk associated with drug development
Opportunities
- Positive clinical trial results for CM-101
- Expansion of CM-101 development to other fibrotic diseases
- Partnerships with larger pharmaceutical companies
Threats
- Clinical trial failures
- Competition from other therapies
- Regulatory hurdles
- Funding challenges
Competitors and Market Share
Key Competitors
- JNJ
- LLY
- BMY
Competitive Landscape
Chemomab faces competition from established pharmaceutical companies with greater resources and existing therapies. Its advantage lies in the novelty of its CCL24-targeting approach, but it needs to demonstrate clinical efficacy and secure funding to compete effectively.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been primarily driven by progress in clinical trials and pipeline development. The company has not yet generated significant revenue.
Future Projections: Future growth depends on the successful development and commercialization of CM-101 and potential expansion into other indications.
Recent Initiatives: Recent initiatives likely include ongoing clinical trials for CM-101 and efforts to secure funding.
Summary
Chemomab Therapeutics is a high-risk, high-reward biotechnology company focused on developing CM-101 for fibrotic diseases. Its future hinges on positive clinical trial results and securing partnerships or funding. The company faces competition and regulatory hurdles but its novel approach could offer a significant advancement in treatment for Systemic Sclerosis.
Similar Companies
ALNY
Alnylam Pharmaceuticals Inc
ALNY
Alnylam Pharmaceuticals Inc
ARRY
Array Technologies Inc
ARRY
Array Technologies Inc
CRSP
Crispr Therapeutics AG
CRSP
Crispr Therapeutics AG
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- ClinicalTrials.gov
- Financial News Outlets
Disclaimers:
This analysis is based on publicly available information and does not constitute financial advice. Market share data is often estimated, and future results are not guaranteed.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Chemomab Therapeutics Ltd DRC
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2019-02-12 | Co-Founder, Chief Scientific Officer, CEO & Executive Director Dr. Adi Mor George Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees - | Website https://www.chemomab.com |
Full time employees - | Website https://www.chemomab.com | ||
Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases in the United States. Its lead product candidate is CM-101, a humanized monoclonal antibody attenuates the basic function of CCL24 that is in phase 2 clinical trial for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.